pancreatic-cancer
7 stories related to this topic, newest first.
The Sydney Morning HeraldAmplia Therapeutics Starts Phase 2b Trial of Narmafotinib for Pancreatic Cancer
Amplia Therapeutics has begun a Phase 2b study testing daily dosing of narmafotinib in newly diagnosed pancreatic cancer patients. The trial combines the drug with standard chemotherapy and will initially enroll 12 patients across Australian sites.
Fox NewsPatient Reports Symptom Improvement in Phase III Trial of Experimental Targeted Chemotherapy for Pancreatic Cancer
Hernando Salcedo, 83, experienced fewer side effects and regained energy after eight TAMP sessions delivered via RenovoRx's RenovoCath device at Miami Cancer Institute. Early TIGeR-PaC trial data showed trends toward better survival and 65% fewer adverse events. Enrollment is exp…
The IndependentUS Cancer Centers Report Surge in Requests for Experimental Pancreatic Cancer Drug
US cancer centers are seeing increased patient requests for daraxonrasib following positive clinical trial results that showed doubled survival rates for advanced pancreatic cancer. The FDA approved an expanded access program for the drug on 1 May, three weeks after the developer…
app.buzzsumo.comDrug Daraxonrasib Extends Survival in Pancreatic Cancer Trial
A small clinical trial found that daraxonrasib, which blocks a family of mutant proteins, helped patients with a deadly form of pancreatic cancer live longer. The drug shrank or halted tumor growth in many participants. Nature reported the findings from the trial published in 202…
Nbc NewsExperimental Pancreatic Cancer Drug Doubles Survival in Advanced Cases
An experimental drug called daraxonrasib has shown it can double survival time for patients with advanced pancreatic cancer when combined with chemotherapy. The Food and Drug Administration has fast-tracked the drug for approval and allowed expanded access outside clinical trials…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Pancreatic Cancer Trial
Revolution Medicines announced that its drug daraxonrasib met primary and secondary endpoints in a Phase 3 trial for pancreatic cancer patients whose disease had progressed on prior treatment. The trial showed a median overall survival of 13.2 months for daraxonrasib compared to…
Substrate placeholder — needs reviewRevolution Medicines Advances Testing of Pancreatic Cancer Treatment Pill
Revolution Medicines is conducting clinical trials for a pill targeting pancreatic cancer. The treatment aims to address a disease with limited effective options. CNBC reported on the company's latest developments in this area.